Mediantechn (ALMDT PA) stock market data APIs
€4.9333
0.04(0.8%)
as of May 8, 2026
Try our APIs with
free plan!
Mediantechn Financial Data Overview
Price chart is built with
Anychart
Median Technologies SA engages in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development with operations spanning in France, the United States, Canada, the United Kingdom, China, and internationally. The company offers iSee for imaging services in clinical trials; eyonis for non-invasive diagnostic tests based on imaging for the diagnosis and treatment of patients suffering from cancer; and iCRO, a central imaging service and AI-powered Imaging Lab. Also, the company focuses on the oncology clinical trials market and the cancer patient care market. The company was founded in 2002 and is based in Valbonne, France.
Prev. Close
4.9333
Open
4.9783
High
4.9851
Low
4.8473
52 wk Range
1.192-7.27
Market Cap
186 M
Shares Outstanding
38 105 K
Revenue
23 469 K
Beta
0.572
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Mediantechn data using free add-ons & libraries
Get Mediantechn Fundamental Data
Mediantechn Fundamental data includes:
- Net Revenue: 23 469 K
- EBITDA: -14 102 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-04-27
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mediantechn News
New
Tempus AI Reinforces Market Position With Collaborations in 2026
Tempus AI TEM continues to expand its footprint in 2026 through a series of strategic collaborations. By partnering with leading pharmaceutical companies, healthcare institutions, and technology innov...
H.C. Wainwright Raises Tempus AI (TEM) Price Target to $95
Tempus AI, Inc. (NASDAQ:TEM) is among the 10 Best New AI Stocks to Buy. On March 9, H.C. Wainwright analyst Yi Chen raised the firm’s price target on Tempus AI, Inc. (NASDAQ:TEM) to $95 from $89 ...
Why Tempus AI (TEM) Is Down 7.5% After 2025 Results, 2026 Outlook And ESOP Shelf Registration - And What's Next
Tempus AI recently reported full-year 2025 results, with revenue rising to US$1.27 billion and net loss narrowing to US$245.03 million, alongside 83% year-over-year Q4 growth driven by diagnostics. ...
Tempus AI Deepens Precision Oncology Role With New HRD And Lung Tools
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Tempus AI (NasdaqGS:TEM) has launched a new AI-driven HRD-RNA algorithm aimed a...
Get Mediantechn fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
